Aigen Investment Management LP Takes Position in Pfizer Inc. $PFE

Key Points

• Aigen Investment Management LP initiated a new position in Pfizer during the fourth quarter, buying 83,314 shares valued at about $2.1 million.
• Other large institutions also added to Pfizer, including Norges Bank, Morgan Stanley, Bank of New York Mellon, Franklin Resources, and Capital World Investors, with institutional ownership now at 68.36%.
• Pfizer recently beat quarterly estimates with $0.75 EPS on $14.45 billion in revenue and reaffirmed FY 2026 EPS guidance of $2.80 to $3.00, while paying a quarterly dividend of $0.43 per share for a 6.6% yield.

Aigen Investment Management LP bought a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 83,314 shares of the biopharmaceutical company's stock, valued at approximately $2,075,000.

Other institutional investors also recently modified their holdings of the company. Norges Bank bought a new stake in Pfizer during the fourth quarter worth about $1,830,986,000. Morgan Stanley lifted its position in Pfizer by 19.2% during the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company's stock worth $2,218,929,000 after purchasing an additional 14,342,946 shares during the period. Bank of New York Mellon Corp lifted its position in Pfizer by 38.9% during the fourth quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company's stock worth $1,208,023,000 after purchasing an additional 13,581,757 shares during the period. Franklin Resources Inc. lifted its position in Pfizer by 47.8% during the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company's stock worth $638,787,000 after purchasing an additional 8,108,887 shares during the period. Finally, Capital World Investors lifted its position in Pfizer by 51.5% during the fourth quarter. Capital World Investors now owns 21,433,890 shares of the biopharmaceutical company's stock worth $533,704,000 after purchasing an additional 7,287,194 shares during the period. Institutional investors own 68.36% of the company's stock.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s new weight-loss data is being viewed as encouraging for its obesity franchise, potentially improving the competitive case for its pipeline and helping sentiment around future growth. Article Title
• Positive Sentiment: Pfizer’s expanded U.S. label for HYMPAVZI is adding to optimism around the hemophilia business by widening the addressable patient pool, which may support future specialty-drug sales. Article Title
• Positive Sentiment: RBC recently upgraded Pfizer to Sector Perform, saying the valuation has reset and the risk-reward profile looks more balanced ahead of pipeline catalysts. Article Title
• Positive Sentiment: Some recent articles argue Pfizer’s Seagen oncology platform and newly acquired obesity assets could help offset patent-expiry and post-COVID revenue pressure, supporting a long-term turnaround thesis. Article Title
• Neutral Sentiment: Analysts currently rate Pfizer around Hold on average, suggesting the market sees limited near-term upside until more pipeline and commercial execution proves out. Article Title
• Negative Sentiment: Bearish commentary continues to highlight Pfizer’s dividend yield as a sign of underlying concern about cash flow, debt, and the company’s ability to support both payouts and reinvestment. Article Title

Analysts Set New Price Targets

PFE has been the subject of several recent analyst reports. Wolfe Research reaffirmed an "underperform" rating and set a $26.00 price objective on shares of Pfizer in a research report on Thursday, May 14th. Argus raised shares of Pfizer from a "hold" rating to a "buy" rating and set a $35.00 price objective for the company in a research report on Monday, March 2nd. Morgan Stanley upped their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock an "equal weight" rating in a research report on Friday, April 10th. Weiss Ratings raised Pfizer from a "hold (c-)" rating to a "hold (c)" rating in a research note on Wednesday, May 6th. Finally, Guggenheim boosted their target price on Pfizer from $35.00 to $36.00 and gave the stock a "buy" rating in a research note on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Pfizer currently has an average rating of "Hold" and a consensus price target of $28.82.

Pfizer Stock Up 0.1%

Shares of NYSE PFE opened at $26.19 on Friday. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The company has a market cap of $149.26 billion, a price-to-earnings ratio of 19.99 and a beta of 0.34. Pfizer Inc. has a 12 month low of $23.11 and a 12 month high of $28.75. The stock has a 50-day moving average price of $26.43 and a two-hundred day moving average price of $26.32.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business's quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 12th. Investors of record on Friday, May 8th were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. The ex-dividend date was Friday, May 8th. Pfizer's dividend payout ratio (DPR) is 131.30%.

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.